MedTrace Logo

AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma

NCT05985694 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-09-10

No results posted yet for this study

Summary

This clinical trial aims to investigate patients with poorly controlled, moderate to severe eosinophilic asthma. The main questions it seeks to answer are

1. Could the AD17002 intranasal immunomodulator improve the clinical condition of eosinophilic asthmatic patients?
2. Could patients self-administer AD17002 via the intranasal route?
3. Is the AD17002 at multiple doses safe for asthmatic patients?
4. Participants will be asked to self-administer two doses per week for a total of 6 weeks (11 doses). A diary on AD17002 usage, adverse events, and reliever medication will be recorded.

Conditions

Interventions

DRUG

AD17002

The dosing days of AD17002 are: Days 1, 4, 8, 11, 15, 18, 22, 25, 29, and 32.

DRUG

Placebo

Formulation buffer. Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32.

Sponsors & Collaborators

  • Taipei Medical University Hospital

    collaborator OTHER

  • Advagene Biopharma Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Yushen Hsu, Ph.D. · Advagene Biopharma

  • Han-Pin Kuo, MD. Ph.D. · Taipei Medical University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-27
Primary Completion
2025-01-28
Completion
2025-04-27

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05985694 on ClinicalTrials.gov